Farah Alsana
Family · Clawson, MINPI 1689421190
Payments from drug & device makers
Across 99 payments — averaging $23.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$432
- AstraZeneca$414
- Alnylam Pharmaceuticals Inc.$281
- Scpharmaceuticals Inc.$242
- Novo Nordisk$227
- Boehringer Ingelheim$197
- plus $580 from 12 others
What the payments were for
- Food & beverage$2,373100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 17 | $432 |
| AstraZeneca | 17 | $414 |
| Alnylam Pharmaceuticals Inc. | 13 | $281 |
| Scpharmaceuticals Inc. | 12 | $242 |
| Novo Nordisk | 6 | $227 |
| Boehringer Ingelheim | 9 | $197 |
| Lilly USA, LLC | 2 | $126 |
| Amgen | 5 | $86 |
| E.r. Squibb & Sons, L.L.C. | 3 | $64 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $62 |
| GSK | 2 | $51 |
| Novartis | 2 | $43 |
| Johnson & Johnson | 2 | $39 |
| Abiomed | 2 | $38 |
| Bayer | 1 | $22 |
| Actelion Pharmaceuticals US, Inc. | 1 | $22 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Pfizer | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,373 in reported general payments places this provider in the 85th percentile of 3,657 family providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 19 | $18,476 |
| EntrestoSacubitril/Valsartan | 23 | $15,465 |
| EliquisApixaban | 11 | $11,737 |
| VerquvoVericiguat | 11 | $7,593 |
| Metoprolol Succinate | 105 | $1,280 |
| Ranolazine ErRanolazine | 29 | $1,071 |
| Rosuvastatin Calcium | 89 | $1,019 |
| Ezetimibe | 31 | $518 |
| Hydralazine Hcl | 38 | $439 |
| ClopidogrelClopidogrel Bisulfate | 22 | $307 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 27 | $281 |
| Metolazone | 14 | $212 |
| Atorvastatin Calcium | 19 | $209 |
| Cilostazol | 18 | $207 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 12 | $172 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $39 | $18,47619 claims |
| NovartisEntresto | $43 | $15,46523 claims |
| PfizerEliquis | $14 | $11,73711 claims |
| MerckVerquvo | $432 | $7,59311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,657 family providers in Michigan.
Other family in Clawson
- Jayme HeimGrandville$663K
- Susan WolgamottBloomfield Township$327K
- Elisheva EllenbergDetroit$150K
- Sarah JohnsonFarmington Hills$119K
- Daniela MaximTroy$112K
- Kelsey PrinceGrand Rapids$87K
- Brent MillerFremont$66K
- Rachael CompeauFlint$62K
- David KocendaLapeer$49K
- Tracy RobertsonBay City$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.